NanoViricides (NYSE-A:NNVC), a US company, targets the unmet medical need for an effective, broadspectrum acute oral antiviral therapy with NV-387.
16 May 2025
NanoViricides: MPox ethics approval enables Phase 2 application
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
NanoViricides: MPox ethics approval enables Phase 2 application
- Published:
16 May 2025 -
Author:
Proactive -
Pages:
10 -
NanoViricides (NYSE-A:NNVC), a US company, targets the unmet medical need for an effective, broadspectrum acute oral antiviral therapy with NV-387.